Bristol-Myers Squibb: Primary Myelofibrosis trials

The registry lists 15 Primary Myelofibrosis studies with Bristol-Myers Squibb as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 7Phase 3 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisRecruitingNCT06073847
• Individual Patient Compassionate Use of FedratinibAvailableNCT03723148
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion DependenceCompletedNCT03194542Phase 2Results posted
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
• A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCompletedNCT00724334Phase 1/2Results posted
• A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid MetaplasiaCompletedNCT00463385Phase 2Results posted
• A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-RuxolitinibCompletedNCT05665192
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
• Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
• Connect® Myeloid Disease RegistryTerminatedNCT01688011
• Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2